Bladder Cancer Weekly

March 09, 2026

Videos

Peer-to-Peer Clinical Conversations

Blue Light Cystoscopy Outcomes and Cost Analysis from the BRAVO Study - Ali Nasrallah

Ali Nasrallah

Ali Nasrallah presents BRAVO study results on blue light cystoscopy cost-effectiveness.

Nadofaragene Firadenovec Management in Real-World BCG-Unresponsive Bladder Cancer: A Case-based Discussion - Mark Tyson

Mark Tyson

Mark Tyson presents a case-based discussion on BCG-unresponsive non-muscle invasive bladder cancer treatment options.

Beyond the Abstracts

A Multi-Modal Approach for Decision Making in Bladder Cancer - Beyond the Abstract

Modulating the PPARγ Pathway Upregulates NECTIN4 and Enhances Chimeric Antigen Receptor (CAR) T Cell Therapy in Bladder Cancer - Beyond the Abstract

Conference Coverage

ASCO GU 2026: BCAN New Faces of Bladder Cancer Survey

ASCO GU 2026: Gemcitabine Intravesical System in Combination with Cetrelimab Versus Chemoradiotherapy in MIBC: SunRISe-2 Final Results

ASCO GU 2026: Updated Clinical Results and Associated Biomarkers from an Ongoing Phase 1 Study of FX-909, a First-in-Class Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Inhibitor, in Patients with Advanced Urothelial Carcinoma

Bayer’s XOFIGO® (Radium-223 Dichloride) plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases

ASCO GU 2026: Design and Implementation of a Patient-Centric Expanded Access Program with Cretostimogene Grenadenorepvec in NMIBC Unresponsive to BCG

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Diagnostic Value of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Staging Histological Subtypes of Invasive Bladder Cancer.

Real-World Data on Neoadjuvant Chemotherapy for Localized Muscle-Invasive Bladder Cancer (2015-2024): A Single-Center Retrospective Study.

Efficacy and Safety of Intravesical Gemcitabine and Docetaxel Combination Therapy in Patients With Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.

Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms.

NECTIN4 Amplification Is a Frequent Event in Central Nervous System Metastases of Urothelial Carcinoma.

Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study.

Temporal Association of US Tobacco Taxation on Smoking Attributable Bladder Cancer Mortality and Disability-Adjusted Life Years.

Computational pathology in bladder cancer: A scoping review.

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Real-world treatment sequences and overall survival in metastatic bladder cancer: The STATES-Bladder study.

External validation and comparison of nomograms for prediction of long-term disease recurrence and survival for bladder cancer patients who undergo radical cystectomy.

A Long Noncoding RNA-based Classifier for Identifying More Aggressive Low-grade Ta Bladder Cancer with Elevated FGFR3 Activity.

Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC